Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492

The proof-of-concept (PoC) study described here examined the efficacy of BGG492 in a human model of photosensitive epilepsy. This was the first study into the effects of selurampanel (BGG492) in patients with epilepsy; primary objectives were to evaluate the efficacy of single oral doses of BGG492 in achieving abolishment of the PPR or a relevant reduction of the SPR in photosensitive patients and to evaluate the time of onset and duration of this response. Secondary objectives were to evaluate the maximal reduction in SPR, to determine the pharmacokinetic (PK) profile of selurampanel, to explore the PK/pharmacodynamic (PD) relationship and to evaluate its safety and tolerability in patients with epilepsy